secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001213900-24-036613
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals enters separation agreement with Dr. Bankole Johnson; consulting termination May 17, 2024
--------------------------------------------------------------------------------

- Separation agreement with Dr. Bankole Johnson signed April 22, 2024; consulting termination effective May 17, 2024.
- One-time separation fee of $54,375; may continue consulting at $850/hour with prior approval.
- Up to $225,000 in milestone payments if certain goals achieved by December 31, 2024.
- Agreement includes general release of claims, confidentiality, and mutual nondisparagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024036613/0001213900-24-036613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024036613/ea0204623-8k_adialphar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-036613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer